Abivax Shares Plummet After Cancer Cases Emerge in Phase 3 Trial for Ulcerative Colitis Drug
Abivax SA's shares dropped as much as 40% after the release of its Phase 3 trial data showed strong efficacy but raised safety concerns due to cancer cases observed in high-dose patients. The mixed results have led to an immediate analyst downgrade and shaken investor confidence.
Tickers: $NVDA
Topics: biotech cancer_cases pharmaceutical ulcerative_colitis